SPERO THERAPEUTICS INC's ticker is SPRO and the CUSIP is 84833T103. A total of 80 filers reported holding SPERO THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.90 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $986,000 | -83.7% | 113,322 | -70.1% | 0.02% | -80.8% |
Q4 2021 | $6,067,000 | -40.7% | 378,932 | -31.8% | 0.12% | -35.6% |
Q3 2021 | $10,229,000 | +120.3% | 555,614 | +67.0% | 0.19% | +123.0% |
Q2 2021 | $4,644,000 | -7.8% | 332,639 | -2.8% | 0.09% | -18.7% |
Q1 2021 | $5,036,000 | -38.2% | 342,113 | -18.6% | 0.11% | -41.5% |
Q4 2020 | $8,150,000 | +95.2% | 420,320 | +12.4% | 0.18% | +28.9% |
Q3 2020 | $4,175,000 | +85.2% | 374,078 | +124.5% | 0.14% | +75.3% |
Q2 2020 | $2,254,000 | +62.7% | 166,606 | -2.8% | 0.08% | +8.0% |
Q1 2020 | $1,385,000 | -3.2% | 171,434 | +15.2% | 0.08% | +13.6% |
Q4 2019 | $1,431,000 | -8.5% | 148,867 | +0.9% | 0.07% | -23.3% |
Q3 2019 | $1,564,000 | -1.8% | 147,543 | +6.7% | 0.09% | +8.9% |
Q2 2019 | $1,592,000 | -11.6% | 138,295 | -1.6% | 0.08% | -18.6% |
Q1 2019 | $1,800,000 | +89.7% | 140,526 | -8.9% | 0.10% | +44.8% |
Q4 2018 | $949,000 | -42.5% | 154,306 | -1.8% | 0.07% | -25.6% |
Q3 2018 | $1,651,000 | -25.5% | 157,058 | +3.9% | 0.09% | -32.8% |
Q2 2018 | $2,217,000 | – | 151,148 | – | 0.13% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Atlas Venture Associates IX, LLC | 1,353,303 | $1,637,497 | 13.93% |
Anson Funds Management LP | 4,159,572 | $5,033,082 | 1.01% |
OUP Management Co., LLC | 249,070 | $301,375 | 0.68% |
Atlas Venture Life Science Advisors, LLC | 1,013,438 | $1,226,260 | 0.19% |
Murchinson Ltd. | 862,700 | $1,043,867 | 0.13% |
Alphabet Inc. | 889,979 | $1,076,874 | 0.07% |
AWM Investment Company, Inc. | 333,400 | $403,414 | 0.06% |
DAFNA Capital Management LLC | 125,000 | $151,250 | 0.05% |
Novo Holdings A/S | 468,902 | $567,371 | 0.04% |
XTX Topco Ltd | 58,368 | $70,625 | 0.01% |